Background
Type 2 diabetes is a chronic condition in which the body does not use insulin effectively, leading to high blood sugar levels over time. For many people, especially those who are overweight or living with obesity, improving glucose control also requires helping with weight loss. Two newer injectable medicines have attracted attention for these goals: cagrilintide, an amylin receptor agonist, and semaglutide, a GLP-1 receptor agonist.
These drugs work through different but complementary pathways. Semaglutide slows stomach emptying, reduces appetite, and improves insulin secretion in a glucose-dependent way. Cagrilintide mimics amylin, a hormone that helps promote fullness and reduce food intake. Researchers have theorized that combining the two could offer stronger benefits for blood sugar and weight management than either drug alone.
The REIMAGINE 2 study was designed to test that idea in adults with type 2 diabetes who were already taking metformin, with or without an SGLT2 inhibitor, and who also had overweight or obesity.
Study design
REIMAGINE 2 was a phase 3, double-blind, randomized, controlled trial conducted in 30 countries. Participants were adults aged 18 years or older with inadequately controlled type 2 diabetes, defined by HbA1c between 7.0% and 10.5%, and a body mass index of at least 25 kg/m2.
People were randomly assigned to one of several once-weekly subcutaneous treatment groups for 68 weeks. The main comparison was between cagrilintide-semaglutide at 2.4 mg each and semaglutide 2.4 mg alone. Other groups included cagrilintide alone, a lower-dose combination of cagrilintide-semaglutide at 1.0 mg each, semaglutide 1.0 mg, and matching placebo. Randomization was stratified by continuous glucose monitoring subgroup, baseline HbA1c category, and country, including whether the participant was enrolled in Japan.
The study was masked, meaning participants, investigators, and sponsor staff did not know which treatment had been assigned within each dose level. The primary endpoint was the change in HbA1c from baseline to week 68 in the full analysis set.
Who took part
A total of 3593 people were screened, and 2713 were randomly assigned to treatment. Of these participants, 42.9% were women and 57.1% were men. Most participants, 81.3%, were White. The average baseline HbA1c was 8.2%, indicating that blood sugar was not well controlled at the start of the study.
Completion was high: 2595 participants, or 95.7%, finished the study, and 2376, or 87.6%, were still on treatment at week 68. This high retention strengthens confidence in the findings.
Main results
The primary outcome showed that cagrilintide-semaglutide at 2.4 mg each lowered HbA1c more than semaglutide 2.4 mg alone. In the efficacy analysis, HbA1c fell by 1.91 percentage points with the combination, compared with 1.75 percentage points with semaglutide alone. The estimated treatment difference was -0.16 percentage points, with a 95% confidence interval from -0.27 to -0.05, and the result was statistically significant (p=0.0035).
Although the numerical difference may appear modest, even small additional reductions in HbA1c can matter clinically, especially in people who remain above target despite standard therapy. The result suggests that adding cagrilintide to semaglutide provides an extra glucose-lowering effect.
The study also included lower-dose and single-agent groups, which helped investigators understand the dose-response pattern and the contribution of each component. The published abstract, however, highlights the strongest comparison: the 2.4 mg combination versus semaglutide 2.4 mg.
Safety findings
Adverse events were common across all active treatment groups, which is expected for incretin-based therapies used in diabetes and obesity care. Events were reported in 86.9% of participants in the cagrilintide-semaglutide 2.4 mg group, 81.2% in the semaglutide 2.4 mg group, 82.2% in the cagrilintide 2.4 mg group, 81.6% in the cagrilintide-semaglutide 1.0 mg group, 78.5% in the semaglutide 1.0 mg group, and 70.5% in the placebo group.
The most common adverse events in the active treatment groups were gastrointestinal, such as nausea, vomiting, diarrhea, and related symptoms. This pattern is consistent with the known class effects of GLP-1 receptor agonists and with prior data on cagrilintide. The abstract does not report any unexpected safety signal, suggesting the combination’s tolerability was broadly in line with what clinicians would anticipate for these agents.
What the results mean
The key message from REIMAGINE 2 is that cagrilintide-semaglutide 2.4 mg each was superior to semaglutide 2.4 mg alone for reducing HbA1c in adults with type 2 diabetes and overweight or obesity who were already receiving metformin, with or without an SGLT2 inhibitor.
This is important because many patients with type 2 diabetes need more than one mechanism of action to reach glycemic goals, especially when excess weight is also part of the clinical picture. A combination therapy that improves both blood sugar and body weight could simplify treatment decisions and potentially improve long-term outcomes if benefits are confirmed in broader practice.
It is also notable that the safety profile appeared consistent with known pharmacology rather than introducing a new pattern of harm. In practical terms, that means the main adverse effects clinicians will need to watch for are likely to be the usual gastrointestinal effects seen with GLP-1-based therapies and related agents.
Clinical context
Semaglutide is already widely used for type 2 diabetes and obesity, and cagrilintide has been studied as a complementary agent because it may enhance satiety and reduce energy intake through a different hormonal pathway. Combining two appetite- and glucose-regulating mechanisms is an appealing strategy, particularly for patients whose diabetes is closely linked to excess body weight.
That said, a statistically significant HbA1c improvement does not automatically mean the combination should replace existing treatments in routine care. Decisions in real-world practice also depend on access, cost, tolerability, injection burden, cardiovascular and renal outcome data, and how much additional weight loss is achieved. Those broader questions will require continued study.
Limitations and next steps
As with any single trial, the results should be interpreted in context. The study population was relatively well characterized, but it may not fully represent all people with type 2 diabetes, including those with lower BMI, more advanced diabetes, or different ethnic and regional backgrounds. Most participants were White, which may limit generalizability.
The abstract also focuses on glycemic outcomes at 68 weeks and short-to-medium-term safety. Longer-term data will be important to understand durability of effect, rare adverse events, and whether improvements in HbA1c translate into fewer diabetes complications.
Future research may also clarify how the combination performs for weight reduction, cardiometabolic risk, adherence, and patient-reported outcomes. If later trials confirm meaningful benefits, CagriSema could become an important option in the management of type 2 diabetes with excess weight.
Conclusion
In adults with type 2 diabetes and overweight or obesity who were already using metformin, with or without an SGLT2 inhibitor, the fixed-dose combination of cagrilintide and semaglutide produced a greater reduction in HbA1c than semaglutide alone. The safety profile was what clinicians would expect from this drug class, with gastrointestinal side effects being the most common.
Overall, REIMAGINE 2 supports the idea that dual hormonal therapy may offer added glycemic benefit over semaglutide alone. For patients and clinicians, this study represents another step toward more effective, weight-aware treatment strategies for type 2 diabetes.
